GRTX Stock - Galera Therapeutics, Inc.
Unlock GoAI Insights for GRTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-3,843,000 | $-259,000 | $-114,000 | $-778,000 | $-368,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-20,160,000 | $-46,951,000 | $-51,226,000 | $-73,368,000 | $-70,553,000 |
| Net Income | $-18,957,000 | $-59,082,000 | $-62,222,000 | $-80,534,000 | $-74,218,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.35 | $-1.33 | $-2.30 | $-3.40 | $-2.98 |
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 10th 2023 | Piper Sandler | Downgrade | Neutral | $0.5← $6 |
Earnings History & Surprises
GRTXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q4 2025 | Nov 13, 2025 | — | $-0.01 | — | — |
Q3 2025 | Aug 13, 2025 | — | $-0.01 | — | — |
Q2 2025 | May 15, 2025 | — | $-0.01 | — | — |
Q1 2025 | Mar 31, 2025 | $-0.30 | $-0.08 | +73.3% | ✓ BEAT |
Q4 2024 | Dec 13, 2024 | $-0.29 | $-0.06 | +79.3% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $0.83 | $-0.07 | -108.5% | ✗ MISS |
Q2 2024 | May 13, 2024 | $-0.29 | $-0.08 | +72.8% | ✓ BEAT |
Q1 2024 | Mar 28, 2024 | $-0.29 | $-0.10 | +64.9% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-0.44 | $-0.33 | +25.0% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.43 | $-0.48 | -11.6% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.36 | $-0.50 | -38.9% | ✗ MISS |
Q1 2023 | Mar 8, 2023 | $-0.50 | $-0.58 | -16.0% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-0.48 | $-0.60 | -25.0% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $-0.47 | $-0.54 | -14.9% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-0.53 | $-0.58 | -9.4% | ✗ MISS |
Q1 2022 | Mar 10, 2022 | $-0.75 | $-0.64 | +14.7% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.65 | $-0.86 | -32.3% | ✗ MISS |
Q3 2021 | Aug 10, 2021 | $-0.79 | $-0.88 | -11.4% | ✗ MISS |
Q2 2021 | May 11, 2021 | $-0.82 | $-0.75 | +8.5% | ✓ BEAT |
Frequently Asked Questions about GRTX
What is GRTX's current stock price?
What is the analyst price target for GRTX?
What sector is Galera Therapeutics, Inc. in?
What is GRTX's market cap?
Does GRTX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to GRTX for comparison